Document is current
Any future updates will be listed below
-
Authors
Targum, Steven D. https://orcid.org/0000-0003-1054-5197
Horan, William P.
Davis, Vicki G.
Breier, Alan
Brannan, Stephen K.
-
Funding
Funding for this research was provided by:
Karuna Therapeutics
- License Information
-
More Information
Article History
Received: 20 March 2024
Revised: 5 December 2024
Accepted: 27 January 2025
First Online: 7 February 2025
Competing interests
: SDT was an employee of Signant Health when this study was conducted. He has received consulting fees from AbbVie, Actinogen Medical Ltd., AZTherapies, BioXcel Therapeutics Inc., CSA Medical Inc., Deerfield Discovery and Development, EcoR1 Capital, EMA Wellness, Evolution Research Group, Frequency Therapeutics, Functional Neuromodulation, Karuna Therapeutics, MapLight Therapeutics, Merck, Neurocrine Biosciences, Supernus Pharmaceuticals Inc., and Pax Neuroscience during the past three years. WPH is an employee of the Department of Psychiatry and Biobehavioral Sciences at the University of California at Los Angeles; he held equity in Karuna Therapeutics at the time the research was performed and is an employee of Bristol Meyers Squibb. SKB was an employee of and held equity in Karuna Therapeutics at the time the research was performed. VGD is a statistical consultant and has received fees from Abyrx, Arkana Laboratories, Boehringer-Ingelheim, Eikonoklastes Therapeutics, Karuna Therapeutics, Harm Reduction Therapeutics, LyGenesis, Renerva, University of North Carolina School of Medicine, Division of Nephropathology, and VeraSci during the past three years. AB is an employee of the Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA and a consultant to Karuna Therapeutics, BioXcel Therapeutics, and Neumarker.
